Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection

N/ACompletedNCT02013180

Bagcilar Training and Research Hospital480 enrolled

Overview

Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the prostate cancer, its specivity is not sufficient. Several PSA variations were defined in order to increase the specivity of the test, but they aren't much more effective than the PSA alone for detection of disease. In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat cancer disease. In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA), zinc/PSA, levels for early detection of the prostate cancer.

Study Type

OBSERVATIONAL

Enrollment

480

Conditions

Prostate Cancer Detection

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: Patients with LUTS and elevated serum PSA levels and/or suspicious rectal examination Exclusion Criteria: usage of zinc included drugs, older prostatic operations, older prostatic radiotherapy, older prostatic biopsies, chronic rectal diseases (anal fissure, hemorrhoid, etc..), PIN(prostatic intraepithelial neoplasia) and ASAP(atypical small acinar proliferation) in pathologic evaluation.

Locations (1)

Bagcilar Training and Research Hospital-Depertmant of Urology

Istanbul, Bagcilar, Turkey (Türkiye)

Outcomes

Primary Outcomes

Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases

Does the zinc/PSA ratio show statistically signifacant difference in patients with prostate cancer?

Time frame: measurement of serum zinc and PSA levels are performed prior to transrectal prostat biopsy; pathologic evaluation of biopsy specimens are performed within 2-3 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.